Beyond the Limits: Clinical Utility of Novel Cardiac Biomarkers

Abstract EN

Preoperative assessment of cardiovascular risk is essential when it comes to extensive noncardiac surgery procedures.

Therefore, accurate and timely diagnosis of myocyte damage is vital.

In modern medical practice it is believed that the so-called “multimarker” approach is the most appropriate and most accurate, but new research points out that there are novel biomarkers which could be used independently.

Studies that evaluate miRNA, H-FABP, and MR-PAMP give encouraging results.

When it comes to miRNA clinical studies show high statistical significance, especially in the case of acute myocardial infarction (P=0.001).

Statistical significance of P=0.007 was found in acute coronary syndrome, when H-FABP was measured.

Biochemical marker MR-PAMP showed statistical significance of P<0.0001 in most clinical studies.